We are live on ! Find out more
OIM

Oracle Investment Management Portfolio holdings

AUM $168M
1-Year Est. Return 42.86%
This Fund
S&P 500
This Quarter Est. Return
-10.53%
1 Year Est. Return
+42.86%
3 Year Est. Return
+864.89%
5 Year Est. Return
+1,153.35%
10 Year Est. Return
+22,228.86%
AUM
$322M
AUM Growth
-$134M
Cap. Flow
-$38.4M
Cap. Flow %
-11.91%
Top 10 Hldgs %
95.27%
Holding
22
New
3
Increased
4
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
MOTS
Motus GI Holdings, Inc. Common Stock
MOTS
+$10.3M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$6.29M
3
CFRX
ContraFect Corporation
CFRX
+$2.91M
4
SLNO
Soleno Therapeutics
SLNO
+$2.42M
5
AXDX
Accelerate Diagnostics
AXDX
+$161K

Top Sells

Rank Stock Value
1
PACB icon
Pacific Biosciences
PACB
+$43.3M
2
AMRN
Amarin Corp
AMRN
+$11.8M
3
ADAP
Adaptimmune Therapeutics
ADAP
+$6.23M
4
TSRO
TESARO, Inc.
TSRO
+$2.2M
5
VRAY
ViewRay, Inc.
VRAY
+$2.03M

Sector Composition

Rank Sector Weight
1 Healthcare 99.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QDEL icon
1
QuidelOrtho
QDEL
$1.14B
$92.9M 28.82%
1,903,558
– –
AMRN
2
Amarin Corp
AMRN
$293M
$70.8M 21.96%
260,079
-32,429
-11% -$11.8M
AXDX
3
DELISTED
Accelerate Diagnostics
AXDX
$48.3M 14.97%
419,802
+1,087
+0.3% +$161K
TSRO
4
DELISTED
TESARO, Inc.
TSRO
$35M 10.86%
471,500
-45,735
-9% -$2.2M
PACB icon
5
Pacific Biosciences
PACB
$432M
$18.9M 5.87%
2,557,764
-6,829,870
-73% -$43.3M
OPK icon
6
Opko Health
OPK
$1.25B
$11.1M 3.44%
3,686,194
– –
CFRX
7
DELISTED
ContraFect Corporation
CFRX
$8.75M 2.71%
7,150
+1,837
+35% +$2.91M
MOTS
8
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$8.63M 2.68%
+9,250
New +$10.3M
BHVN
9
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$6.45M 2%
+174,535
New +$6.29M
SLNO
10
DELISTED
Soleno Therapeutics
SLNO
$6.3M 1.95%
245,546
+83,009
+51% +$2.42M
BIOL
11
DELISTED
Biolase, Inc.
BIOL
$6.11M 1.9%
2,469
– –
AGEN
12
Agenus
AGEN
$275M
$3.23M 1%
69,237
-7,165
-9% -$299K
VRML
13
DELISTED
Vermillion, Inc.
VRML
$2.95M 0.91%
9,825,289
– –
BIIB icon
14
Biogen
BIIB
$30.4B
$1.93M 0.6%
6,368
– –
AXDX
15
CALL
DELISTED
Accelerate Diagnostics
AXDX
$405K 0.13%
61,350
-35,440
-37% -$5.25M
ADAP
16
DELISTED
Adaptimmune Therapeutics
ADAP
$304K 0.09%
52,921
-844,573
-94% -$6.23M
PACB icon
17
CALL
Pacific Biosciences
PACB
$432M
$281K 0.09%
1,909,600
+1,859,600
+3,719% +$11.8M
QDEL icon
18
CALL
QuidelOrtho
QDEL
$1.14B
$52K 0.02%
144,100
-30,900
-18% -$1.84M
AMRN
19
CALL
Amarin Corp
AMRN
$293M
$4K ﹤0.01%
+5,000
New +$1.82M
KDNY
20
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-22,308
Closed -$820K
VRAY
21
DELISTED
ViewRay, Inc.
VRAY
– –
-216,862
Closed -$2.03M
EPZM
22
DELISTED
Epizyme, Inc
EPZM
– –
-28,884
Closed -$306K

Similar funds

BIO
Blue Investment Opportunities Miami Beach, Florida $168M AUM 21.32% 1-Year Est. Return
OBWA
Oak Barrel Wealth Advisory Reston, Virginia $167M AUM
EECFX
EnCap Energy Capital Fund XII Houston, Texas $169M AUM
PW
Pandora Wealth Oakbrook Terrace, Illinois $165M AUM 18.5% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
AIMU
Allianz Investment Management US Minneapolis, Minnesota $160M AUM 4.75% 1-Year Est. Return
HIA
Harvest Investment Advisors Tallahassee, Florida $176M AUM
ACA
AG Campbell Advisory Baltimore, Maryland $158M AUM

Oracle Investment Management's Q4 2018 Portfolio in Review

As of Q4 2018, Oracle Investment Management held 22 positions worth $322M, down 29% from $457M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Oracle Investment Management withdrew a net $38.4M in Q4 2018, closing 3 positions and reducing 7 holdings. Its most notable exit was ViewRay, Inc., an estimated $2.03M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Oracle Investment Management opened a new position in Motus GI Holdings, Inc. Common Stock worth $8.63M.

  • Oracle Investment Management's largest Q4 2018 buy was Motus GI Holdings, Inc. Common Stock: 9,250 shares worth $8.63M.
  • Oracle Investment Management added most to ContraFect Corporation in Q4 2018, an estimated $2.91M increase.
  • Oracle Investment Management's biggest Q4 2018 reduction was Pacific Biosciences, cutting an estimated $43.3M.
  • Oracle Investment Management fully exited ViewRay, Inc. in Q4 2018, selling an estimated $2.03M.
  • Oracle Investment Management's ten largest holdings make up 95% of its $322M portfolio in Q4 2018.
  • Oracle Investment Management opened 3 new positions and closed 3 in Q4 2018.
  • Oracle Investment Management's portfolio value fell 29% quarter-over-quarter to $322M.

Based on Oracle Investment Management's 13F filing for Q4 2018, filed 14 Feb 2019.